Phase I Study of TAS-106 in Combo With Carboplatin
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of the combination
of TAS-106 and carboplatin that can be given to patients with advanced cancer or cancer that
has spread.
Objectives:
Primary Objectives:
To determine the maximum tolerated dose (MTD) of the combination of TAS-106 and carboplatin
administered by intravenous infusion every 3 weeks.
To perform Pharmacokinetic (PK) analysis of TAS-106 and carboplatin
Secondary objectives:
To assess the antitumor activity of TAS-106 combined with carboplatin
To investigate the relationship between selected biomarkers and efficacy and safety outcomes.